問卷

TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Cardiovascular Diseases

更新時間:2023-09-19

陳勉成
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

10Cases

2010-11-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-01-08 - 2011-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2006-12-01 - 2008-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2006-12-01 - 2009-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2009-09-01 - 2013-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2017-04-01 - 2018-12-31

Phase III

A PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLINDED ENDPOINT EVALUATION (PROBE) PARALLEL GROUP STUDY COMPARING EDOXABAN VS. VKA IN SUBJECTS UNDERGOING CATHETER ABLATION OF NON-VALVULAR ATRIAL FIBRILLATION (ELIMINATE-AF)
  • Condition/Disease

    Non-valvular atrial fibrillation (AF)

  • Test Drug

    Edoxaban (DU-176b)

Participate Sites
6Sites

Terminated5Sites

2006-12-18 - 2010-09-07

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Terminated13Sites

2010-08-30 - 2012-11-30

Phase III

A Phase III, Prospective, Randomized, Double-Blind, PlaceboControlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients with Atrial Fibrillation
  • Condition/Disease

    Atrial Fibrillation

  • Test Drug

    MK-6621

Participate Sites
16Sites

Terminated16Sites

2009-05-01 - 2015-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2007-10-15 - 2008-10-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites